Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/02/03 00:56:58」(JST)

wiki en

Afelimomab (MAK 195F) is an anti-TNFα monoclonal antibody. Administration of afelimomab reduces the concentration of interleukin-6 in patients with sepsis, but reduces mortality only marginally.^[1]^[2]

References

^ Rondon, E.; Venkataraman, R. (2005). "Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels". Critical Care 9 (5): E20. doi:10.1186/cc3798. PMC 1297624. PMID 16277704.
^ Panacek, E. A.; Marshall, J. C.; Albertson, T. E.; Johnson, D. H.; Johnson, S.; MacArthur, R. D.; Miller, M.; Barchuk, W. T.; Fischkoff, S.; Kaul, M.; Teoh, L.; Van Meter, L.; Daum, L.; Lemeshow, S.; Hicklin, G.; Doig, C.; Monoclonal Anti-TNF: a Randomized Controlled Sepsis Study Investigators (2004). "Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels". Critical Care Medicine 32 (11): 2173–2182. doi:10.1097/01.CCM.0000145229.59014.6C. PMID 15640628.

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

English Journal

Emerging drugs for the treatment of sepsis.

Kotsaki A, Giamarellos-Bourboulis EJ.Author information University of Athens, Medical School, 4th Department of Internal Medicine, Athens, Greece.AbstractINTRODUCTION: Despite improvement in medical care, severe sepsis and septic shock remain an unmet medical need. Their incidence is steadily increasing and the worldwide mortality ranges between 30% and 50%. This generates the need for agents that modulate the immune function of the host.
Expert opinion on emerging drugs.Expert Opin Emerg Drugs.2012 Sep;17(3):379-91. doi: 10.1517/14728214.2012.697151. Epub 2012 Jul 11.
INTRODUCTION: Despite improvement in medical care, severe sepsis and septic shock remain an unmet medical need. Their incidence is steadily increasing and the worldwide mortality ranges between 30% and 50%. This generates the need for agents that modulate the immune function of the host.AREAS COVERE
PMID 22780561

Whose loss is it? Human electrophysiological correlates of non-self reward processing.

Fukushima H, Hiraki K.Author information The University of Tokyo, Tokyo, Japan. fukush@flet.keio.ac.jpAbstractTo recognize whether another person's action results in a good or bad outcome is imperative for social learning, as well as for understanding the behavior of others in a broad context. Recent studies have reported that a scalp-surface event-related potential (ERP) called medial-frontal negativity (MFN), considered to be an index of negative reward processing, is generated when perceiving not only one's own losses, but also those of others. This suggests that the same neural mechanisms operate in monitoring one's own actions and in perceiving the consequences of the actions of others. To further elucidate the properties of this "observational" MFN, this study examined whether its amplitude differs with different observational targets. In a gambling task, participants observed the performances of non-self agents: a human friend and PC programs. The outcomes of the decisions of these agents were not associated with the participants' own benefits. ERP results showed that the MFN-like pattern was significantly elicited only when observing the outcomes of decisions made by human agents. Furthermore, self-reported measures of empathy were positively associated with the magnitude of the observational MFN. These findings suggest that the neural activity in non-self reward processing reflects a socioemotional state generated by the target of observation, as well as an empathetic trait of the individual.
Social neuroscience.Soc Neurosci.2009;4(3):261-75. doi: 10.1080/17470910802625009. Epub 2009 Feb 4.
To recognize whether another person's action results in a good or bad outcome is imperative for social learning, as well as for understanding the behavior of others in a broad context. Recent studies have reported that a scalp-surface event-related potential (ERP) called medial-frontal negativity (M
PMID 19191194

MONARCS: statistical or clinical meaning?

Jaimes FA.
Critical care medicine.Crit Care Med.2005 Sep;33(9):2144; author reply 2144-6.
PMID 16148507

Related Pictures

★リンクテーブル★

リンク元

「mab」

Afelimomab
Monoclonal antibody
Type	F(ab')2 fragment
Source	Mouse
Target	TNFα
Identifiers
CAS Number	156227-98-4
ATC code	L04AB03
ChemSpider	none
KEGG	D07436
(what is this?) (verify)

　　[★]

関: モノクローナル抗体

mab

abciximab
adahmumab
adalimumab
afelimomab
alemtuzumab
apolizumab
arcitumomab
basiliximab
bevacizumab
cantuzumab
certolizumab
cetolizumab
cetuximab
clenoliximab
daclizumab
デノスマブ denosumab 抗RANKL抗体
eculizumab
edrecolomab
efalizumab
epratuzumab
galiximab
gemtuzumab
ibritumomab
インフリキシマブ infliximab 抗TNF-α抗体クローン病 Ph⁺ALL
inotuzumab
keliximab
natalizumab
nebacumab
omalilzumab
omalizumab
oregovomab
palivizumab
panitumumab
pertuzumab
pexelizumab
リツキシマブ rituximab：抗CD20抗体：慢性リンパ性白血病、B細胞リンパ腫

[1] Rondon, E.; Venkataraman, R. (2005). "Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels". Critical Care 9 (5): E20. doi:10.1186/cc3798. PMC 1297624. PMID 16277704.

[2] Panacek, E. A.; Marshall, J. C.; Albertson, T. E.; Johnson, D. H.; Johnson, S.; MacArthur, R. D.; Miller, M.; Barchuk, W. T.; Fischkoff, S.; Kaul, M.; Teoh, L.; Van Meter, L.; Daum, L.; Lemeshow, S.; Hicklin, G.; Doig, C.; Monoclonal Anti-TNF: a Randomized Controlled Sepsis Study Investigators (2004). "Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels". Critical Care Medicine 32 (11): 2173–2182. doi:10.1097/01.CCM.0000145229.59014.6C. PMID 15640628.

匿名

検索

案内

案内

afelimomab